静脉溶栓后出血性转化研究进展  

Research progress in hemorrhagic transformation after intravenous thrombolysis

作　　者：许雯樱 田力[2] 李进伟[1] 薛维爽[1] 滕伟禹[1] Xu Wenying;Tian Li;Li Jinwei;Xue Weishuang;Teng Weiyu(Department of Neurology, First Affiliated Hospital of China Medical University, Shenyang 110001, China;Department of Gerontology, Shengjing Hospital Affiliated to China Medical University, Shenyang 110004, China)

机构地区：[1]中国医科大学附属第一医院神经内科,沈阳110001 [2]中国医科大学附属盛京医院老年病科,沈阳110004

出　　处：《中华神经科杂志》2019年第4期334-339,共6页Chinese Journal of Neurology

基　　金：国家科技部"十三五"重大专项项目(2017ZX10201101);中国医科大学2018年度临床医学重大专项建设计划项目(111-3110118036).

摘　　要：脑卒中日益成为威胁人类的三大重要疾病之一,其中以急性缺血性脑卒中最为常见。目前静脉溶栓治疗已成为急性缺血性脑卒中的首选,但大量研究表明静脉溶栓会增加出血性转化的风险。文中将对重组组织型纤溶酶原激活剂溶栓后出血性转化的临床分型、发生率、发生机制及危险因素的最新进展做一综述,并探讨出血性转化的可能预测指标,为临床溶栓治疗提供新的参考。Stroke has increasingly become one of the three major diseases threatening human beings, among which acute ischemic stroke is the most common. Intravenous thrombolysis has become the first choice for acute ischemic stroke, but a large number of studies have shown that intravenous thrombolysis increases the risk of hemorrhagic transformation. The latest advances in clinical types, incidence, mechanism and risk factors of hemorrhagic transformation after thrombolysis with recombinant human tissue plasminogen activator are reviewed in this article, and the possible predictors of hemorrhagic transformation are discussed, aiming to provide new reference for clinical thrombolytic therapy.

关 键 词：卒中 组织型纤溶酶原激活剂 静脉溶栓 出血性转化 

分 类 号：R743.3[医药卫生—神经病学与精神病学]